FeesSafety
Pluang+

Coinbase completes Aerodrome and Velodrome token upgrade, restores new AERO and VELO transfers.

Protocol Fundamentals
08 Nov 2026, 19:57 WIB
Tokenpost
View Source
Neutral
Coinbase completes Aerodrome and Velodrome token upgrade, restores new AERO and VELO transfers.

Coinbase has finished converting Aerodrome Finance (AERO) and Velodrome Finance (VELO) tokens to a new Aero (AERO) token. The exchange has resumed send and receive functions for both AERO and VELO tokens. However, Coinbase no longer supports deposits or withdrawals of the old AERO tokens and warns that old tokens sent to Coinbase deposit addresses may be lost and unrecoverable. Users should ensure they use the new tokens for transactions on Coinbase.

Coinbase's migration of Aerodrome Finance (AERO) and Velodrome Finance (VELO) tokens to a new Aero token is the subject, with Pluang market data as context. As of Nov 08, 2026 23:21 WIB, among 50 major cryptocurrencies on Pluang, 13 rose and 36 fell. Notable movers include SNX at Rp2.927 with a 2.98% decline and 100% buy order activity, VET at Rp93 down 2.91% with a nearly balanced sell/buy split, and ATOM at Rp24.303 down 2.83% with 90% buy orders.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
2 hours ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
2 hours ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
3 hours ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
3 hours ago
Rocket Lab delays Neutron rocket debut to 2027, impacting revenue and profitability outlook.

Rocket Lab delays Neutron rocket debut to 2027, impacting revenue and profitability outlook.

Rocket Lab has delayed the debut of its Neutron reusable medium-class rocket to 2027 due to a setback with the first-stage tank. This delay increases the company's reliance on its Electron rocket launches and Space Systems division, putting its path ...

Market News
Bearish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App